Nektar Therapeutics (NASDAQ:NKTR) shares saw an uptick in trading volume on Monday after Aegis raised their price target on the stock to $24.00. 15,334,116 shares changed hands during trading, an increase of 1,150% from the previous session’s volume of 1,227,150 shares.The stock last traded at $22.11 and had previously closed at $15.50.

NKTR has been the topic of several other reports. Roth Capital set a $23.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research report on Saturday, March 4th. Jefferies Group LLC reissued a “buy” rating and set a $17.00 price target (up from $15.00) on shares of Nektar Therapeutics in a research report on Friday, March 3rd. Piper Jaffray Companies set a $25.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, BTIG Research began coverage on Nektar Therapeutics in a research report on Friday, January 6th. They set a “buy” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $22.86.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 87,500 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $12.35, for a total value of $1,080,625.00. Following the sale, the chief executive officer now directly owns 265,408 shares of the company’s stock, valued at $3,277,788.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard W. Robin sold 8,636 shares of the stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $13.14, for a total value of $113,477.04. Following the completion of the sale, the chief executive officer now directly owns 169,272 shares in the company, valued at $2,224,234.08. The disclosure for this sale can be found here. Insiders sold 465,689 shares of company stock worth $6,389,028 over the last ninety days. 6.10% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in Nektar Therapeutics by 3.2% in the third quarter. Bank of New York Mellon Corp now owns 1,825,071 shares of the biopharmaceutical company’s stock valued at $31,355,000 after buying an additional 56,079 shares during the last quarter. Wells Fargo & Company MN boosted its position in Nektar Therapeutics by 6.1% in the third quarter. Wells Fargo & Company MN now owns 115,326 shares of the biopharmaceutical company’s stock valued at $1,981,000 after buying an additional 6,604 shares during the last quarter. New York State Teachers Retirement System boosted its position in Nektar Therapeutics by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 255,224 shares of the biopharmaceutical company’s stock valued at $3,132,000 after buying an additional 1,300 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Nektar Therapeutics by 1.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,353,625 shares of the biopharmaceutical company’s stock valued at $57,615,000 after buying an additional 61,918 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock valued at $188,481,000 after buying an additional 749,496 shares during the last quarter. 86.80% of the stock is currently owned by hedge funds and other institutional investors.

The firm’s market capitalization is $3.40 billion. The stock has a 50-day moving average of $13.78 and a 200-day moving average of $14.35.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The firm had revenue of $37.45 million for the quarter, compared to analyst estimates of $40.83 million. During the same period in the previous year, the business posted ($0.40) EPS. Nektar Therapeutics’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities analysts expect that Nektar Therapeutics will post ($1.35) EPS for the current year.

Your IP Address:

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.